IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma
NCT01333605
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Hodgkin Lymphoma
Interventions
DRUG:
IGEV
Sponsor
Fudan University